跳至主要内容
临床试验/CTRI/2020/07/026858
CTRI/2020/07/026858招募中3 期

Cost-effectiveness of early stoppage of empirical antibiotic therapy at clinical improvement in pediatric cancer patients with high risk febrile neutropenia nested within an ongoing open label randomized control trial

AIIMS0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
招募中
发起方
AIIMS

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Age 2-18 yrs
  • 2. De novo and relapsed AML & ALL undergoing induction & reinduction with febrile neutropenia

排除标准

  • 1. Already enrolled once in previous episode
  • 2. Retrovirus positive patients
  • 3. Patients who require >= 3rd line antibiotics during febrile neutropenia episode prior to becoming afebrile
  • 4. Patients who require therapeutic antifungals during febrile neutropenia episode prior to enrolment
  • 5. Patients who require ionotropic support / mechanical ventilation during treatment course for febrile neutropenia episode prior to enrolment
  • 6. Severe renal function impairment (defined as a creatinine clearance below 30 ml/min) during treatment course for febrile neutropenia prior to enrolment
  • 7. The clinical or microbiological or radiologic focus of infection during treatment course for febrile neutropenia prior to enrolment
  • 8. Patient undergone stem cell transplant
  • 9. Denying consent

研究者

发起方
AIIMS

相似试验